12 completed, 1 terminated. 7 Phase 1, 6 Phase 2.
By phase and status
Follow Cyclerion Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers
Olinciguat, Itraconazole - Healthy | Phase 1 | Completed | Cyclerion Therapeutics | 24 | 2019-05-03 | 2019-07-15 |
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers
[14C]-praliciguat - Healthy Volunteers | Phase 1 | Completed | Cyclerion Therapeutics | 8 | 2019-03-01 | 2019-06-19 |
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers
[14C]-olinciguat - Healthy Volunteers | Phase 1 | Completed | Cyclerion Therapeutics | 8 | 2019-01-17 | 2019-04-03 |
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers
IW-1973, Itraconazole - Healthy | Phase 1 | Completed | Cyclerion Therapeutics | 24 | 2018-04-12 | 2019-04-03 |
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
IW-1701, Placebo - Sickle Cell Disease | Phase 2 | Completed | Cyclerion Therapeutics | 88 | 2017-12-22 | 2023-07-21 |
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
IW-1973, Placebo Oral Tablet - Heart Failure With Preserved Ejection Fraction | Phase 2 | Completed | Akebia Therapeutics | 196 | 2017-11-07 | 2022-09-15 |
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
IW-1973, Placebo - Type 2 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Completed | Akebia Therapeutics | 156 | 2017-08-01 | 2022-09-15 |
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
Olinciguat, Matching Placebo - Achalasia | Phase 2 | Terminated | Cyclerion Therapeutics | 9 | 2017-04-06 | 2021-05-04 |
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
IW-1973, Placebo - Diabetes Mellitus, Type 2, Hypertension | Phase 2 | Completed | Cyclerion Therapeutics | 26 | 2017-02-28 | 2020-08-31 |
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
Matching Placebo, IW-1973 - Diabetes Mellitus, Type 2, Hypertension | Phase 2 | Completed | Cyclerion Therapeutics | 11 | 2016-09-01 | 2020-04-16 |
A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects
IW-1701, Placebo - Healthy | Phase 1 | Completed | Cyclerion Therapeutics | 67 | 2016-05-01 | 2019-04-03 |
Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
IW-1973, Matching Placebo Tablet - Healthy | Phase 1 | Completed | Cyclerion Therapeutics | 54 | 2015-11-01 | 2019-04-03 |
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
IW-1701, Matching Placebo - Healthy | Phase 1 | Completed | Cyclerion Therapeutics | 24 | 2015-10-01 | 2019-04-03 |
Conditions studied
Diabetes Mellitus, Type 2 (2) · Hypertension (2) · Anemia, Sickle Cell (1) · Esophageal Achalasia (1) · Heart Failure (1)
Interventions
praliciguat (6) · Itraconazole (2)
Countries
United States (13) · Canada (1) · Lebanon (1) · United Kingdom (1)
Top investigators
Bina Tejura, MD (2) · John Hanrahan, MD (2) · Jelena Seferovic, MD PhD (1) · John Hanrahan, MD MPH (1)
Results publications
PMID 31858186, PMID 32105984, PMID 33079154, PMID 33328269, PMID 39833553